McDermott DF - Search Results

1

Progressive immune dysfunction with advancing disease stage in renal cell carcinoma.

Braun DA, Street K, Burke KP, Cookmeyer DL, Denize T, Pedersen CB, Gohil SH, Schindler N, Pomerance L, Hirsch L, Bakouny Z, Hou Y, Forman J, Huang T, Li S, Cui A, Keskin DB, Steinharter J, Bouchard G, Sun M, Pimenta EM, Xu W, Mahoney KM, McGregor BA, Hirsch MS, Chang SL, Livak KJ, McDermott DF, Shukla SA, Olsen LR, Signoretti S, Sharpe AH, Irizarry RA, Choueiri TK, Wu CJ. Braun DA, et al. Among authors: mcdermott df. Cancer Cell. 2021 May 10;39(5):632-648.e8. doi: 10.1016/j.ccell.2021.02.013. Epub 2021 Mar 11. Cancer Cell. 2021. PMID: 33711273 Free PMC article.

2

Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma.

Atkins MB, Regan M, McDermott D. Atkins MB, et al. Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6342S-6S. doi: 10.1158/1078-0432.CCR-040029. Clin Cancer Res. 2004. PMID: 15448028 Review.

3

Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion.

Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A, O'Neill A, Mier J, Ochoa AC. Zea AH, et al. Cancer Res. 2005 Apr 15;65(8):3044-8. doi: 10.1158/0008-5472.CAN-04-4505. Cancer Res. 2005. PMID: 15833831

4

Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, Febbo P, Upton M, Lechpammer M, Signoretti S. Atkins M, et al. Clin Cancer Res. 2005 May 15;11(10):3714-21. doi: 10.1158/1078-0432.CCR-04-2019. Clin Cancer Res. 2005. PMID: 15897568

5

Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy.

Upton MP, Parker RA, Youmans A, McDermott DF, Atkins MB. Upton MP, et al. Among authors: mcdermott df. J Immunother. 2005 Sep-Oct;28(5):488-95. doi: 10.1097/01.cji.0000170357.14962.9b. J Immunother. 2005. PMID: 16113605

6

Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.

McDermott DF, Regan MM, Atkins MB. McDermott DF, et al. Clin Genitourin Cancer. 2006 Sep;5(2):114-9. doi: 10.3816/CGC.2006.n.027. Clin Genitourin Cancer. 2006. PMID: 17026799 Review.

7

Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response.

McDermott DF, Atkins MB. McDermott DF, et al. Semin Oncol. 2006 Oct;33(5):583-7. doi: 10.1053/j.seminoncol.2006.06.004. Semin Oncol. 2006. PMID: 17045087 Review.

8

Update on the application of interleukin-2 in the treatment of renal cell carcinoma.

McDermott DF. McDermott DF. Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):716s-720s. doi: 10.1158/1078-0432.CCR-06-1872. Clin Cancer Res. 2007. PMID: 17255299 Retracted. Review.

9

Immunotherapy for metastatic renal cell carcinoma.

McDermott DF, Rini BI. McDermott DF, et al. BJU Int. 2007 May;99(5 Pt B):1282-8. doi: 10.1111/j.1464-410X.2007.06818.x. BJU Int. 2007. PMID: 17441925 Review. No abstract available.

10

Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma.

Avigan DE, Vasir B, George DJ, Oh WK, Atkins MB, McDermott DF, Kantoff PW, Figlin RA, Vasconcelles MJ, Xu Y, Kufe D, Bukowski RM. Avigan DE, et al. Among authors: mcdermott df. J Immunother. 2007 Oct;30(7):749-61. doi: 10.1097/CJI.0b013e3180de4ce8. J Immunother. 2007. PMID: 17893567 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

301 results

Search Page